Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 7/2016

01-07-2016 | Editorial

Vonoprazan: MarKed Competition for PPIs?

Authors: David R. Scott, Elizabeth A. Marcus, George Sachs

Published in: Digestive Diseases and Sciences | Issue 7/2016

Login to get access

Excerpt

Contemporary therapies for the treatment of acid-related diseases such as gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), as well as Helicobacter pylori infection, rely on acid suppression for symptom relief, healing, and eradication, respectively. Inhibition of the gastric H+,K+-ATPase, the final step in the acid secretion pathway, by proton pump inhibitors has been the treatment of choice since the approval of omeprazole for clinical use 30 years ago [1]. PPIs were a vast improvement over the H2 receptor antagonists (H2RAs) and antacids for symptom relief and for healing of GERD and PUD. …
Literature
1.
Lindberg P, Brandstrom A, Wallmark B, Mattsson H, Rikner L, Hoffmann KJ. Omeprazole: the first proton pump inhibitor. Med Res Rev. 1990;10:1–54.CrossRefPubMed
2.
Gedda K, Scott D, Besancon M, Lorentzon P, Sachs G. Turnover of the gastric H+, K+-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology. 1995;109:1134–1141.CrossRefPubMed
3.
Cederberg C, Lind T, Rohss K, Olbe L. Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients. Digestion. 1992;53:171–178.CrossRefPubMed
4.
Sakai T, Aoyama N, Kita T, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res. 2001;18:721–727.CrossRefPubMed
5.
Furuta T, Shirai N, Ohashi K, Ishizaki T. Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. Methods Find Exp Clin Pharmacol. 2003;25:131–143.CrossRefPubMed
6.
Wallmark B, Briving C, Fryklund J, et al. Inhibition of gastric H+,K+-ATPase and acid secretion by SCH 28080, a substituted pyridyl(1,2a)imidazole. J Biol Chem. 1987;262:2077–2084.PubMed
7.
Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther.. 2005;108:294–307.CrossRefPubMed
8.
Matsukawa J, Kogame A, Tagawa Y, Inatomi N. Radiographic localization study of a novel potassium-competitive acid blocker, vonoprazan, in the rat gastric mucosa. Dig Dis Sci. (Epub ahead of print). doi:10.​1007/​s10620-016-4100-y.
9.
Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81:1145–1151.CrossRefPubMed
10.
Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339:412–420.CrossRefPubMedPubMedCentral
11.
Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6:e94.CrossRefPubMedPubMedCentral
12.
Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685–695.CrossRefPubMed
Metadata
Title
Vonoprazan: MarKed Competition for PPIs?
Authors
David R. Scott
Elizabeth A. Marcus
George Sachs
Publication date
01-07-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4164-8

Other articles of this Issue 7/2016

Digestive Diseases and Sciences 7/2016 Go to the issue

Original Article

Knockdown of Astrocyte Elevated Gene-1 Inhibits Activation of Hepatic Stellate Cells

Stanford Multidisciplinary Seminars

Biliary Cystadenoma: A Suggested “Cystamatic” Approach?

Original Article

Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn’s Disease: A Hospital-Based Cohort Study

Editorial

Confocal Laser Endomicroscopy in the Management of IBD: Clearly Superior?

Rapid Communications

Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS)

Original Article

Time to Relapse in Children with Crohn’s Disease Treated with Azathioprine and Nutritional Therapy or Corticosteroids
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits